cigarettes containing tobacco substitutes, not for medical purposes; cigarillos; electronic cigarettes; tips of yellow amber for cigar and cigarette holders; liquid solutions for use in electronic cigarettes; cigarette tips; flavourings, other than essential oils, for use in electronic cigarettes; flavorings, other than essential oils, for use in electronic cigarettes; cigarette cases; oral vaporizers for smokers; pipe racks for tobacco pipes.;
Domain names similar "ALLO"
News around "ALLO" trademark
News sentiment analysis powered by sentiment-insight.com
Allogene Therapeutics Inc (NASDAQ:ALLO) ended Q3 2023 with $497.7 million in cash, cash equivalents, and investments. Research and development expenses were $46.0 million for the third quarter of 2023. Company continues to expect its cash runway to fund operations into 2H 2025.
2023-10-29
negative
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Deliver On Growth Plans?
Allogene Therapeutics (NASDAQ:ALLO) had a cash runway of about 2.0 years as of June 2023. Its cash burn was US$241m over the trailing twelve months. With the cash burn rate up 14% in the last year, it seems that the company is ratcheting up investment in the business over time. The company spent a huge amount relative to its market value.
2023-08-02
neutral
Allogene Therapeutics: Q2 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a loss of $78 million in its second quarter. On a per-share basis, the South San Francisco, California-based company said it had a lost of 53 cents. The results topped Wall Street expectations.
2023-05-22
negative
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Allogene Therapeutics (NASDAQ:ALLO) reported just US$234k in the last twelve months. The company burnt through US$223m last year, which is 25% of the company's market value. The crucial factor is whether the company will grow its business going forward. We conducted an in-depth investigation and identified 2 warning signs for the company.
2023-03-02
positive
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
Allogene Therapeutics, Inc. (Nasdaq: ALLO) is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer. The company will participate in two upcoming investor conferences.
2023-02-28
negative
Allogene Therapeutics: Q4 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) reported a loss of $94.8 million in its fourth quarter. The South San Francisco, California-based company said it had a Loss of 66 cents per share. The results topped Wall Street expectations.
Sign Up
